Literature DB >> 23670231

Evaluation of heart failure biomarker tests: a survey of statistical considerations.

Arkendra De1, Kristen Meier, Rong Tang, Meijuan Li, Thomas Gwise, Shanti Gomatam, Gene Pennello.   

Abstract

Biomarkers assessing cardiovascular function can encompass a wide range of biochemical or physiological measurements. Medical tests that measure biomarkers are typically evaluated for measurement validation and clinical performance in the context of their intended use. General statistical principles for the evaluation of medical tests are discussed in this paper in the context of heart failure. Statistical aspects of study design and analysis to be considered while assessing the quality of measurements and the clinical performance of tests are highlighted. A discussion of statistical considerations for specific clinical uses is also provided. The remarks in this paper mainly focus on methods and considerations for statistical evaluation of medical tests from the perspective of bias and precision. With such an evaluation of performance, healthcare professionals could have information that leads to a better understanding on the strengths and limitations of tests related to heart failure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23670231     DOI: 10.1007/s12265-013-9470-3

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  29 in total

Review 1.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification.

Authors:  Richard Simon; Michael D Radmacher; Kevin Dobbin; Lisa M McShane
Journal:  J Natl Cancer Inst       Date:  2003-01-01       Impact factor: 13.506

2.  On criteria for evaluating models of absolute risk.

Authors:  Mitchell H Gail; Ruth M Pfeiffer
Journal:  Biostatistics       Date:  2005-04       Impact factor: 5.899

Review 3.  Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve.

Authors:  Nancy R Cook
Journal:  Clin Chem       Date:  2007-11-16       Impact factor: 8.327

4.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

5.  Randomized clinical trials with biomarkers: design issues.

Authors:  Boris Freidlin; Lisa M McShane; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2010-01-14       Impact factor: 13.506

Review 6.  Missing data in the regulation of medical devices.

Authors:  Gregory Campbell; Gene Pennello; Lilly Yue
Journal:  J Biopharm Stat       Date:  2011-03       Impact factor: 1.051

7.  Multiple biomarkers for the prediction of first major cardiovascular events and death.

Authors:  Thomas J Wang; Philimon Gona; Martin G Larson; Geoffrey H Tofler; Daniel Levy; Christopher Newton-Cheh; Paul F Jacques; Nader Rifai; Jacob Selhub; Sander J Robins; Emelia J Benjamin; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

8.  Use and misuse of the receiver operating characteristic curve in risk prediction.

Authors:  Nancy R Cook
Journal:  Circulation       Date:  2007-02-20       Impact factor: 29.690

9.  Gene-expression profiling for rejection surveillance after cardiac transplantation.

Authors:  Michael X Pham; Jeffrey J Teuteberg; Abdallah G Kfoury; Randall C Starling; Mario C Deng; Thomas P Cappola; Andrew Kao; Allen S Anderson; William G Cotts; Gregory A Ewald; David A Baran; Roberta C Bogaev; Barbara Elashoff; Helen Baron; James Yee; Hannah A Valantine
Journal:  N Engl J Med       Date:  2010-04-22       Impact factor: 91.245

10.  Categorising continuous variables.

Authors:  D G Altman
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

View more
  5 in total

Review 1.  Advances in induced pluripotent stem cells, genomics, biomarkers, and antiplatelet therapy highlights of the year in JCTR 2013.

Authors:  Emanuele Barbato; Enrique Lara-Pezzi; Craig Stolen; Angela Taylor; Paul J Barton; Jozef Bartunek; Paul Iaizzo; Daniel P Judge; Lorrie Kirshenbaum; Burns C Blaxall; Andre Terzic; Jennifer L Hall
Journal:  J Cardiovasc Transl Res       Date:  2014-07       Impact factor: 4.132

2.  Biomarkers and heart disease: what is translational success?

Authors:  Francis G Spinale; Craig M Stolen
Journal:  J Cardiovasc Transl Res       Date:  2013-06-04       Impact factor: 4.132

3.  Myocardial and Peripheral Ischemia Causes an Increase in Circulating Pregnancy-Associated Plasma Protein-A in Non-atherosclerotic, Non-heparinized Pigs.

Authors:  Lasse Bach Steffensen; Christian Bo Poulsen; Jeong Shim; Marie Bek; Kevin Jacobsen; Cheryl A Conover; Jacob Fog Bentzon; Claus Oxvig
Journal:  J Cardiovasc Transl Res       Date:  2015-10-06       Impact factor: 4.132

4.  Interleukin-6 and adhesion molecules VCAM-1 and ICAM-1 as biomarkers of post-acute myocardial infarction heart failure.

Authors:  D O C Lino; I A Freitas; G C Meneses; A M C Martins; E F Daher; J H C Rocha; G B Silva Junior
Journal:  Braz J Med Biol Res       Date:  2019-11-25       Impact factor: 2.590

5.  A Pathologist-Annotated Dataset for Validating Artificial Intelligence: A Project Description and Pilot Study.

Authors:  Sarah N Dudgeon; Si Wen; Matthew G Hanna; Rajarsi Gupta; Mohamed Amgad; Manasi Sheth; Hetal Marble; Richard Huang; Markus D Herrmann; Clifford H Szu; Darick Tong; Bruce Werness; Evan Szu; Denis Larsimont; Anant Madabhushi; Evangelos Hytopoulos; Weijie Chen; Rajendra Singh; Steven N Hart; Ashish Sharma; Joel Saltz; Roberto Salgado; Brandon D Gallas
Journal:  J Pathol Inform       Date:  2021-11-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.